Fair Value Calculator Fair Value Calculator
EN DE

PT Dosni Roha Indonesia Tbk, through its subsidiaries, (ZBRA) Fair Value & Analysis

Healthcare · ID · Market cap 26.7B IDR

PD PT Dosni Roha Indonesia Tbk, through its subsidiaries, ZBRA · JK
Price50.00 IDR
Fair Value423.66 IDR
Upside+747.3%
Quality41/100
Watch PT Dosni Roha Indonesia Tbk, through its subsidiaries, for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range 423.66 IDR – 1,041 IDR

Fair value as of: Jul 13, 2026

From 13 valuation models · updated today

Fair value updated Jul 13, 2026 — revised from 7,410 IDR to 423.66 IDR (−94.3%) since Jun 24, 2026.

Price vs Fair Value (12 months)

50.00 IDR 50.00 IDR Fair Value 423.66 IDR Jul 2025 Jul 2026

12‑month range 50.00 IDR – 50.00 IDR · fair‑value band 423.66 IDR – 1,041 IDR · the 50.00 IDR price screens below the 423.66 IDR fair value. As of Jul 13, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

PT Dosni Roha Indonesia Tbk, through its subsidiaries, (ZBRA) currently trades at 50.00 IDR, while our model-based Fair Value estimate is 423.66 IDR — implying the stock looks roughly 747.3% undervalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, PT Dosni Roha Indonesia Tbk, through its subsidiaries, generated revenue of 941B IDR at a net margin of -33.6%. Revenue declined 89.5% year over year. It earns a return on equity of -28.3%. Net debt stands at 1.1T IDR. Fundamentals as of Jul 13, 2026

Our scenario range runs from 423.66 IDR (bear case) to 1,041 IDR (bull case); at 50.00 IDR, the current price sits below that range. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside — at 747%, ZBRA screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 941B IDR
Revenue growth (YoY) -89.5%
Net margin -33.6%
Return on equity -28.3%
Free cash flow 293B IDR FY2023
Operating margin -127%
More key figures
EPS (TTM) -50.87 IDR
EPS growth (YoY) -50.5%
Net debt 1.1T IDR FY2023

Figures from reported company fundamentals (EODHD) · as of Jul 13, 2026. TTM = trailing twelve months.

About the company

PT Dosni Roha Indonesia Tbk, through its subsidiaries, engages in trading, export-import, logistic, and information technology (IT) businesses in Indonesia. It operates through Logistics, Technology and Information, Medical Equipment Trade, and Others segment. The company distributes health care and consumer goods; and provides freight forwarding and warehousing. It also offers transportation management services; marketing goods; and courier and other business support services. The company was formerly known as PT Zebra Nusantara Tbk and changed its name to PT Dosni Roha Indonesia Tbk in March 2022. PT Dosni Roha Indonesia Tbk was founded in 1987 and is headquartered in Jakarta Selatan, Indonesia. PT Dosni Roha Indonesia Tbk operates as a subsidiary of PT Trinity Healthcare.

Revenue & earnings trend

FY2019 – FY2023 · reported fiscal years

PT Dosni Roha Indonesia Tbk, through its subsidiaries, reported revenue of 1.7T IDR in FY2023 versus 15.7B IDR in FY2019, a compound +223.7%/yr. Reported net income was −139B IDR in FY2023.

Revenue +223.7%/yr
FY19 15.7B IDR
FY20 14.7B IDR
FY21 3.5T IDR
FY22 3.0T IDR
FY23 1.7T IDR
Net income
FY19 −994M IDR
FY20 −1.6B IDR
FY21 29.0B IDR
FY22 −112B IDR
FY23 −139B IDR

Is ZBRA fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "PT Dosni Roha Indonesia Tbk, through its subsidiaries, Fair Value". https://www.fairvalue-calculator.com/stock/ZBRA.JK

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation M1CK34 R$999.49 R$1,236 +24%
Cencora, Inc COR $271.28 $175.74 -35%
Cardinal Health, Inc CAH $201.74 $92.07 -54%
Sigma Healthcare Limited SIGGF $2.35 $0.7800 -67%
Shanghai Pharmaceuticals Holding 601607 ¥15.96 ¥45.15 +183%
Henry Schein, Inc HSIC $78.67 $67.77 -14%
Galenica AG GALNF $115.00 $98.28 -15%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥20.81 ¥25.18 +21%
Medipal Holdings MEPDF $18.35 $29.88 +63%
Jointown Pharmaceutical Group 600998 ¥4.87 ¥9.24 +90%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is PT Dosni Roha Indonesia Tbk, through its subsidiaries, (ZBRA) undervalued?
As of Jul 13, 2026, our model estimates a fair value of 423.66 IDR versus a price of 50.00 IDR — about +747% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ZBRA?
Our model-based fair value for PT Dosni Roha Indonesia Tbk, through its subsidiaries, is 423.66 IDR (as of Jul 13, 2026), built from audited fundamentals. The current price is 50.00 IDR.
What is the quality score of ZBRA?
PT Dosni Roha Indonesia Tbk, through its subsidiaries, has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of PT Dosni Roha Indonesia Tbk, through its subsidiaries, (ZBRA)?
PT Dosni Roha Indonesia Tbk, through its subsidiaries, reported trailing-twelve-month revenue of about 941B IDR (latest available figure, as of Jul 13, 2026).
What is the net profit margin of ZBRA?
The net profit margin of PT Dosni Roha Indonesia Tbk, through its subsidiaries, is about -33.6%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

14 days Pro free · no card

Unlock the full PT Dosni Roha Indonesia Tbk, through its subsidiaries, analysis — and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.